Literature DB >> 6848299

Central effects of beta-adrenoceptor antagonists.

S A Salem, D G McDevitt.   

Abstract

The central effects of atenolol, a cardioselective beta-adrenoceptor antagonist, were investigated in six healthy men. Two flash-fusion threshold (2FFT), simple reaction time (SRT), digital copying (DCT), symbol-digit modalities (SDMT), and Gibson's spiral maze tests (GSMT) and mood rating scales for tension, alertness, depression, detachment, and anxiety were used. Each subject took 50, 100, 200, and 400 mg atenolol and identical placebo orally in a randomized, double-blind, crossover study and the psychomotor tests were performed at 0, 2, 3, 5, and 8 hr. 2FFT was prolonged at 3 hr after all doses and at 2 and 5 hr with 100, 200, and 400 mg. The maximum effect was achieved with 200 mg and mean 2FFT correlated with mean plasma atenolol concentration. SRTs were prolonged after all doses at between 2 and 5 hr. The DCT and the retest gain of the SDMT were both lower than after placebo at 2 hr with 100, 200, and 400 mg. The time taken to perform the GSMT was not altered by active drug, but the number of errors was lower at 2 hr with 100 and 200 mg. The self-rating mood scales showed a subjective decrease in tension 2 hr after 400 mg. The results show that atenolol exerts central effects in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848299     DOI: 10.1038/clpt.1983.7

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Memory performance by mild hypertensives following beta-adrenergic blockade.

Authors:  D J Madden; J A Blumenthal; L G Ekelund; D S Krantz; K C Light; D C McKee
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.

Authors:  D Currie; R V Lewis; D G McDevitt; A N Nicholson; N A Wright
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

3.  Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway.

Authors:  A N Nicholson; N A Wright; M B Zetlein; D Currie; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

Review 4.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

5.  Cognitive function in hypertensives treated with atenolol or propranolol.

Authors:  D M Palac; R D Cornish; W J McDonald; D A Middaugh; D Howieson; S P Bagby
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

Review 6.  Memory function--effects of different antihypertensive drugs.

Authors:  P J Richardson; M A Wyke
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy.

Authors:  C Dahlöf; E Dimenäs; B Olofsson
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

8.  The relationship between serum concentrations and central nervous system actions of metoprolol.

Authors:  F M Gengo; J C Ermer; C Carey; G C Kalonaros; W B McHugh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

9.  Beta-blockers and psychometric performance: studies in normal volunteers.

Authors:  D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Central effects of the calcium antagonist, nifedipine.

Authors:  D G McDevitt; D Currie; A N Nicholson; N A Wright; M B Zetlein
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.